SLC5A2 and type 2 diabetes mellitus: Several meta-analysis studies reported that patients with type 2 diabetes mellitus who used SGLT2 inhibitors had a significantly higher risk of UTI than those who used a placebo or other oral anti-diabetic agents [4,5].